Optimize treatment for bone metastases to ensure uninterrupted bone protection[1,2]

	ZOMETA Information

Dosed continually every 3 or 4 weeks as an infusion over no less than 15 minutes, ZOMETA is proven to protect against bone complications and their debilitating effects.[1,2]

ZOMETA delays bone complications from breast, prostate, lung and other solid tumors

In breast cancer:

• In the pivotal trial, ZOMETA demonstrated comparable efficacy versus pamidronate in delaying bone complications (373 days vs. 363 days) in patients with breast cancer or multiple myeloma[3]
• In a recent Japanese study, ZOMETA significantly reduced skeletal complications by 39% compared to placebo (P=.027) in women with bone metastases from breast cancer[3]

In prostate cancer:

• ZOMETA delayed bone complications vs. placebo by 22% over 5 months (P=0.009)[3]
• ZOMETA-treated patients had significantly fewer skeletal related events[1,4] 25% less than placebo (p-0.021)

Proven efficacy in patients with multiple myeloma and patients with documented bone metastases from breast cancer[1,2,5]

The first bisphosphonate proven effective in patients with bone metastases from solid tumors in a study of over 500 patients with any cancer other than breast, prostate, or multiple myeloma.[1,2]

1. ZOMETA prescribing information.
   
2. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057. Accessed September 22, 2005 at: http://www.jco.org/cgi/content/full/21/21/4042.
   
3. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-82.
   
4. Data on file (ISE/ISS). Novartis Pharmaceuticals Corporation.
   
5. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-387.